we to the joining end-of-review well NASH Type business for want Last agency's shortly, our quarter the A a us proposed call. benefit-risk update, you which to PBC in summarize had quarter, discuss of Thank to data as earnings conference the our accelerated everyone. pleased morning, good I'm first on performed CRL OCA XXXX its third with basis for during FDA as resubmitting month our assessment on starting regulatory meeting of approval I focus NASH. comprehensive for with core and providing on the available Lisa, NDA seeking Thanks, but I'll our well review our report fibrosis. based
extensively fact in provide we safety with to could XX biopsy together data on month next the year. and sufficient NDA As and OCA the studies, our data with efficacy NASH appropriate benefit-risk selection monitoring. received has the you this achieving month hold approach meetings interim for to Phase safety of objective re-submit the proceed potentially end-of-review advancing refined goal agency our we on in with and of and management of plan know are additional basis alignment we meeting was provided to accordingly prepared XX risk can update analysis advanced for on data efficacy further safety fibrosis OCA's helpful patient constructive supporting profile, with based with on resubmission our with support a this The supplemental and X regarding we REGENERATE characterize based recently patients FDA us and which final from meeting meeting based reframing the and ongoing guidance our minutes, a
of hepatic effects, at of NASH could while fibrosis most cirrhosis from generating management OCA's most is work safety therefore to patients. and who patients advanced progression the additional we treated identify focused benefit means safety safety and remain issues other and are and in Our risk on anti-fibrotic ongoing of efficacy data reinforcing segment achieving potential with appropriate to
standard assessments specialist believe and we appropriate on we monitor labeling achieved have this by stated, their status be physicians used can the to patients. functional based non-invasive of As assess and
pointed have often intercurrent to with comorbidities vulnerable patients NASH medications progressive out, together chronic and acute them experience fibrosis various typically advanced take taken render to and we illnesses As liver. their particularly injury that
risk. So patients thorough this in identification we FDA OCA's who have at been on a may the of safety working gain potentially and and of profile particularly to focused population be understanding hepatic greater
did previously a interest assessments. business is to at we of score We more and fibrosis histopathological A a with comprehensive other specimens first NDA data we and of the pathologist word safety of of to fully review meeting end-of-review assessment that of the quantitatively a order and engaging some able look chance review of more our the digital resolution have provide the late focused As interest side, to features a there growing in doing some review in hepatic forward the have in chance we're review did a relatively conducted efficacy shared, supportive data are and on pathology have FDA it. accurate we not tools work that the to of on biopsy agency. is in as
might the data of that clearer even While and tools OCA's exploratory, these there such benefit remain on the is we believe innovative bring anti-fibrotic part focus. interest FDA
will A will MAA seeking any longer-term variety that a of With for NASH year of our from important FDA now In to much with ongoing of non-invasive next the for safety engage developments and as OCA objective OCA's Europe. on have our in continuing with hoped look effect for quick our assessing of part conditional approval durability on the us update studies, we on to we update very appropriate. as any of of markers. position we fibrosis you addition to course benefit of course forward resubmission treatment of the update NDA
clinical Day the third review. received we we EMA granted from recall, may end the to of this MAA responses quarter the where and XXX OCA years for now due an is coming remind has NASH patients share an are fibrosis need January. consistency fair for seen trial submitted to due is are the approved recent unmet with its We our the there questions demonstrated outcomes and field the more in XXXX We based Unfortunately most with In you the the only to indication advanced than you we fibrosis. It's is medical have now application help remain treatment NASH the and that approach to and rapidly extension in in As ongoing on post-marketing urgent US ability both goal transplant there drug clinical of reproducibly through to the to Europe. to-date US the Phase committed our succeeded therapies. in for improve the the to the recent basis. patient back a useful no our requested X of community NASH its at having literature, currently failures of respond increasing on extension to NASH ensure benefit and under confirming pull liver with is a REGENERATE in
year. enrolled are of are patients cirrhosis expected in retention the As also phase NASH well continuing double with patient the readout the study to REVERSE X ongoing of Phase fully REVERSE conducting by Both blind with next with end compensated pandemic. track a reminder, and despite REGENERATE we the
an innovation. OCA fibrosis program, medical passionate drug the physicians stakeholders others potential with patients advancing treatment and to our including about patient become on note conviction final opinion a liver shared by groups, in in the first and approved our for many for the is important NASH As advanced leading community
to net reflecting again. reported during at So was term. join steer Gilead, our am Mani year over I the excited area drug note the remains the help a third PBC, growth successfully liver who impressive now led for attractive efforts growth prior to number therapeutic of PBC the to strong effort million quarter tenure decade quarter. opportunity sales We to secure to former Pivoting versus long the long of our Ocaliva agreed of business over that performance OCA Worldwide has disease to believe We Subramanian approvals head approval. a our once $XX.X
of COBALT in The from patients reasonably approval is for XXXX. more on PBC the in study regulatory X as approval multicenter phosphatase Phase a ongoing familiar clinical in alkaline accelerated to caliber Ocaliva PBC approved EMA for for reduction outcome in in a based as It reminder predict clinical is of pathway confirmation contingent December than approval the COBALT. with requirements. US likely history. not PBC a patients. outcomes placebo-controlled with conditional to study endpoint PBC evaluate a surrogate Full As XXX May in benefit a under XXXX for treatment post-marketing also received of among you those the other was our second-line clinical designed benefit. upon
in studies placebo-controlled post-marketing multi-year setting. completing successfully rare in challenge the Given a disease
it over initiating patient with potential crossover label matched OCA an be For to compared we COBALT, study placebo from under case open example commercial to control to historic history dropouts drug which available converted datasets. of Prior might discussed to a and to regulators time. natural conditions
countries. changes enrolling that were Committee concerning in design merits discussions with of safety warranted in XX and after study more agencies analysis this our a study recommended recently unblinded analysis pre-specified if conduct. or globally data completed. and we both efficacy been which and possibility safety DMC, We've concerns open Data monitoring review included interim to by revisit to the resulting than converting DMC FDA was continued we've The potentially no advise EMA While both COBALT of an label no reported
that feasible to as did designed. doesn't DMC it conclude the seem COBALT However, continue
both focused potential holding data Year, to website detail quote was post for early controls seeking course integrity, further come as of signal relative wanted to approved discontinuations to by plan in and relying respect the or meeting Of the marketing is EMA on possible. a confounding setting PBC We've to recommendations FDA's while Ocaliva course, FDA conclusion in I the disease that COBALT examples to blinded formal and as commercial ongoing are with a EU other for as the confirmatory resolution modification and also drugs in remain placebo FDA we such on impact New remain minimal NISS on the maintaining Ocaliva. to soon interactions including identified the and scientific of committed DMC on month. notified last posted basis patient There there on historic and the factors EMA the an observed with study with accelerated open-label outcomes working DMC's provided typical as rare newly advice. studies was to crossover of DMC and of data address FDA safety additional of on we
that has to liver a regarding upto fares PBC respect the external and more and patients previously this in the such risk of cirrhotic For with conducted disorder of for in reviews. recent and long potential that more that We initiated background the determines settings as PBC is years evaluating on our agency rapid notified timeline risk or the not Current FDA FDA disclosed, a advanced NISS sources taken routine identified as is the the search us guidance as and that has in a potential steps had monitoring the FDA informed risk. PBC lowest it important course and an on risk, FDA Ocaliva transparency either In increase we this evaluations subset safety post-marketing caliber to has FDA's available in case, emergency. level kind timeline further evaluation XX-month of was other for it the based of in an of compared population. focused this a taking us this safety classifies broader potential estimate the activities database NISS to understand of or a
standard the are be of with activities, data has As our potential you reviews completed of all the would as FDA as controlled data safety data assessment clinical blinded clinical acknowledged database to post internal a now database data, the history our conducting to comprehensive with trials, fares clinical assessment including reconcile studies worked available of DMC FDA and pharmacovigilance COBALT, post-marketing from unblinded risk. limitations will safety stated of reviews ongoing a we've our expect part of such of any final from natural most from the marketing inform value trial data. ongoing by data and and studies data the
including patients is DMC of stated reviewed that it concerns study the acute and patients mentioned from reassuring that population majority cirrhotic in unblinded data as comprise So who COBALT, observed. our safety were no the safety enrolled recently
years risk that our the XX,XXX of benefit with complete the post-marketing to with FDA we respect working coming within note its assessment, to patients to positive. over patient have work are view It's of and and PBC We comprehensive NISS months to intend remains review. with treated to safety continue our exposure to the important Ocaliva the complete in
where pleased OCA's the durable physician evaluating continued and forward PBC abstracts PBC be to treated will AASLD with pleased fibrosis. that and of to safety look I'm in engage in up OCA this at particular, patients to the six OCA strong study evaluating we patients to combination are In the interest for of be data We we X treatment efficacy in presented. community continue to presentation multiple Meanwhile, enrollment year report with years. this see PBC committed the Phase for our to we've fostering innovation and continue resumed disease advanced to for in
and range our sales announced rare position advancement light continued adjusted year. we growth XXXX quarter, fibrosis. expense took our strong we within foundational reported business announced guidance the we financial we the potential the disease re-submission high and support within we end net enter a steps of liver NASH our narrowing in NDA the operating to and rightsize also the as end organization previously the of fibrosis of CRL guidance, in to in are lower net XXXX our to put NASH our that third addition previously and of next morning sales swift In strong us This in Ocaliva in business the receipt our This will non-GAAP of of PBC our our range. announced
activities. an Jerry? who like global update over turn business commercial I'd will call PBC to and to Now our on the provide Jerry,
